Search

Displaying results 3601 - 3610 of 5895 in total
  1. Drug

    PDPSC18

    go.drugbank.com/drugs/DB05167
    Experimental

    PDPSC18 is therapeutic DNA vaccine designed to fight chronic infections with the Hepatitis B virus, entering phase I clinical trials.

  2. Drug

    Bavituximab

    go.drugbank.com/drugs/DB05136
    Investigational

    Bavituximab is a chimeric Anti-PS monoclonal antibody analog which is used to potentially treat cancers and viral infections. … It binds to phosphatidylserine and other exposed host cell lipids when induced by cellular stress. Additional analogs in the class include 3G4, 2aG4, 9d2 and Hu3g4.

  3. Drug

    CYT007-TNFQb

    go.drugbank.com/drugs/DB05758
    Experimental

    CYT007-TNFQb is an active immunization therapy that aims at providing a novel treatment to people suffering from RA or psoriasis. … The vaccine should allow for administration of low amounts of drug to individual patients (in the microgram range) and for convenient dosing schedules.

  4. Drug

    Eucalyptol

    go.drugbank.com/drugs/DB03852
    ApprovedInvestigationalNutraceutical

    Eucalyptol is naturally produced cyclic ether and monoterpenoid. Eucalyptol is an ingredient in many brands of mouthwash and cough suppressant. It controls airway mucus hypersecretion and asthma via anti-inflammatory cytokine inhibition....

    Mixtures: Cal Mo Dol Ont
  5. Drug

    8-chlorotheophylline

    go.drugbank.com/drugs/DB14132
    Experimental

    a number of effects including nervousness, restlessness, insomnia, headache, and nausea, which are primarily attributed to its ability to block the adenosine receptor [A33889, A1539]. … 8-Chlorotheophylline is a stimulant drug of the xanthine chemical class, with physiological effects similar to caffeine.

  6. Drug

    NS-2359

    go.drugbank.com/drugs/DB05805
    Investigational

    NS2359 is a triple monoamine re-uptake inhibitor with a new, unique drug profile expected to yield important benefits compared to existing treatments of depression. … This mode of action is expected to produce an optimal reduction in all disease symptoms and the possibility of an earlier onset of action compared to antidepressants already on the market.

  7. Drug

    Plozalizumab

    go.drugbank.com/drugs/DB12520
    Investigational

    The recruitment of macrophages to the arterial wall is believed to be a critical step in the development of atherosclerosis. … Preclinical studies suggest that CCR2 plays an important role in the trafficking of monocytes and macrophages to sites of inflammation.

  8. Drug

    KB109

    go.drugbank.com/drugs/DB16531
    Experimental

    KB109 is a prebiotic to feed healthy bacteria for them to to outcompete multi-drug resistance organisms.

  9. Drug

    Serdexmethylphenidate

    go.drugbank.com/drugs/DB16629
    Approved

    [A230698, A230708] Serdexmethylphenidate is a prodrug of the CNS stimulant [dexmethylphenidate], a common first-line treatment for ADHD, that is combined with [dexmethylphenidate] to provide extended plasma

  10. Drug

    Factor IX Complex (Human)

    go.drugbank.com/drugs/DB11330
    ApprovedInvestigational

    Factor IX Complex is a sterile, lyophilized concentrate composed of a number of Vitamin K-dependent clotting factors found in functioning human plasma. Also known as prothrombin complex concentrate, products containing this complex often...